Restricted accessResearch articleFirst published online 2013-10
Disability caused by multiple sclerosis is associated with the number of extra cranial venous stenoses: possible improvement by venous angioplasty. Results of a prospective study
Chronic cerebrospinal venous insufficiency (CCSVI) was recently described in patients with multiple sclerosis (MS). The hypothesis of the vascular aetiology provides a new approach in the investigation and treatment of MS.
Methods:
Our open-label study included 94 MS patients who fulfilled ultrasound sonographic criteria required for CCSVI. The internal jugular and/or azygous veins by a catheter venography were dilated.
Results:
In 34.8% of the patients unilateral, in 65.2% bilateral venous abnormalities and in 2.1% no luminal obstructions were demonstrated. The patient group with the higher disability score had a significantly higher number of venous lesions (P < 0.005). Significant improvement of clinical disability in relapsing-remitting patients was (P < 0.001) achieved. In our study no stents were used. Re-stenosis occurred in 21.7% of the patients.
Conclusion:
The number of venous narrowings is higher in more disabled patients. A significant improvement in clinical disability in the relapsing-remitting group was observed.
WeinshenkerBG, RiceGPA, NoseworthyJH, CarriereW, BaskervilleJ, EbersGC. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability.Brain1989; 112: 133–46.
AscherioA, MungerKL. Enviromental risk factor for multiple sclerosis. Part I: The role of infection.Ann Neurol2007; 61: 288–99.
5.
ZamboniP, GaleottiR, MenegattiE. Chronic cerebrospinal venous insufficiency in patients with multiple sclerosis.J Neurol Neurosurg Psychiatry2009; 80: 392–9.
6.
ZamboniP, GaleottiR, MenegattiE. A prospective open-label study of endovascular treatment of chronic cerebrospinal venous insufficiency.J Vasc Surg2009; 50: 1348–58.
PolmanCH, ReingoldSC, EdanG. Diagnostic criteria for multiple sclerosis; 2005 revisions to the ‘McDonald Criteria’.Ann Neurol2005; 58: 840–6.
11.
KurtzkeJF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).Neurology1983; 33: 1444–52.
12.
SimkaM, KosteckiJ, ZaniewskiM, MajewskiE, HartelM. Extracranial Doppler sonographic criteria of chronic cerebrospinal venous insufficiency in the patients with multiple sclerosis.Int Angiol2010; 29: 109–14.
13.
LudygaT, KazibudzkiM, SimkaM. Endovascular treatment for chronic cerebrospinal venous insufficiency: is the procedure safe?Phlebology2010; 25: 286–95.
14.
PetrovI, GrozdinskiL, KaninskiG, IlievN, IloskaM, RadevA. Safety profile of endovascular treatment for chronic cerebrospinal venous insufficiency with multiple sclerosis.J Endovasc Ther2011; 18: 314–23.
15.
DoeppF, PaulF, ValduezaJM, SchmiererK, SchreiberSJ. No cerebrovascular venous congestion in patients with multiple sclerosis.Ann Neurol2010; 68: 173–83.
16.
SundströmP, WåhlinA, AmbarkiK, BirganderR, EklundA, MalmJ. Venous and cerebrospinal fluid flow in multiple sclerosis: a case-control study.Ann Neurol2010; 68: 255–9.
17.
KrogiasC, SchröderA, WiendlH, HohlfeldR, GoldR. Chronic cerebrospinal venous insufficiency and multiple sclerosis: critical analysis and first observation in an unselected cohort of MS patients.Nervenarzt2010; 81: 740–6.
18.
Van den BergPJ, VisserLH. Extra-transcranial echo colour Doppler in the diagnosis of chronic cerebrospinal venous insufficiency.Phlebology2012; 27: 107–13.
19.
MenegattiE, GenovaV, TessariM. Reproducibility of colour Doppler in chronic cerebrospinal venous insufficiency associated with multiple sclerosis.Int Angiol2010; 29: 121–6.
20.
ZivadinovR, MarrK, CutterG. Prevalence, sensitivity, and specificity of chronic cerebrospinal insufficiency in MS.Neurology2011; 77: 138–44.
21.
BastianelloS, RomaniA, ViselnerG. Chronic cerebrospinal venous insufficiency in multiple sclerosis: clinical correlates from a multicentre study.BMC Neurol2011; 11: 132–8.
22.
CentonzeD, FlorisR, StefaniniM. Proposed chronic cerebrospinal venous insufficiency criteria do not predict multiple sclerosis risk or severity.Ann Neurol2011; 70: 51–8.
23.
ZivadinovR, GaleottiR, HojnackiD. Value of MR venography for detection of internal jugular vein anomalies in multiple sclerosis: a pilot longitudinal study.AJNR Am J Neuroradiol2011; 32: 938–46.
24.
ZaharchukG, FischbeinNJ, RosenbergJ, HerfkensRJ, DakeMD. Comparison of MR and contrast venography of the cervical venous system in multiple sclerosis.AJNR Am J Neuroradiol2011; 32: 1482–9.
25.
RadakD, KolarJ, AntonićZ. Chronic cerebrospinal venous insufficiency in multiple sclerosis: fact or fiction!?Cardiovasc Intervent Radiol2011; 34: 1115–6.
26.
ZivadinovR, RamanathanM, DolicK. Chronic cerebrospinal venous insufficiency in multiple sclerosis: diagnostic, pathogenetic, clinical and treatment perspectives.Expert Rev Neurother2011; 11: 1277–94.
27.
LeeB, LaredoJ, NevilleR. Embriogenic background of truncular venous malformation in the extracranial venous pathways as the cause of chronic cerebrospinal venous insufficiency.Int Angiol2010; 29: 95–108.
28.
ZamboniP, GaleottiR, Weinstock-GuttmanB, KennedyC, SalviF, ZivadinovR. Venous angioplasty in patients with multiple sclerosis. Results of a non-randomized pilot study.Eur J Vasc Endovas Surg2012; 43: 116–22.
29.
BeelenR, MaeneL, CastenmillerP, DecoeneV, DegrieckI. Evolution in quality of life and epidemiological impact after endovascular treatment of chronic cerebrospinal venous insufficiency in patients with multiple sclerosis.Phlebology2012; 27 (Suppl. 1): 187–9.
30.
BaracchiniC, PeriniP, CausinF, CalabreseM, RinaldiF, GalloP. Progressive multiple sclerosis is not associated with chronic cerebrospinal venous insufficiency.Neurology2011; 77: 844–50.
31.
FerliniA, BovolentaM, NeriM. Custom CGH array profiling of copy number variations (CNVs) on chromosome 6p21.32 (HLA locus) in patients with venous malformations associated with multiple sclerosis.BMC Med Genet2010; 11: 64–73.
32.
SalviF, BartolomeiI, BuccellatoE, GaleottiR, ZamboniP. Venous angioplasty in multiple sclerosis: neurological outcome at two years in a cohort of relapsing-remitting patients.Funct Neurol2012; 27: 55–9.
